190 related articles for article (PubMed ID: 33598527)
1. Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.
Keshavan A; Wellington H; Chen Z; Khatun A; Chapman M; Hart M; Cash DM; Coath W; Parker TD; Buchanan SM; Keuss SE; Harris MJ; Murray-Smith H; Heslegrave A; Fox NC; Zetterberg H; Schott JM
Alzheimers Dement (Amst); 2021; 13(1):e12131. PubMed ID: 33598527
[TBL] [Abstract][Full Text] [Related]
2. Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.
Keshavan A; Wellington H; Chen Z; Khatun A; Chapman M; Hart M; Cash DM; Coath W; Parker TD; Buchanan SM; Keuss SE; Harris MJ; Murray-Smith H; Heslegrave A; Fox NC; Zetterberg H; Schott JM
Alzheimers Dement (Amst); 2020; 12(1):e12097. PubMed ID: 32999915
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
4. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
[TBL] [Abstract][Full Text] [Related]
5. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
Leitão MJ; Silva-Spínola A; Santana I; Olmedo V; Nadal A; Le Bastard N; Baldeiras I
Alzheimers Res Ther; 2019 Nov; 11(1):91. PubMed ID: 31759396
[TBL] [Abstract][Full Text] [Related]
6. P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status.
Campbell MR; Ashrafzadeh-Kian S; Petersen RC; Mielke MM; Syrjanen JA; van Harten AC; Lowe VJ; Jack CR; Bornhorst JA; Algeciras-Schimnich A
Alzheimers Dement (Amst); 2021; 13(1):e12190. PubMed ID: 34027020
[TBL] [Abstract][Full Text] [Related]
7. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.
Willemse EAJ; Tijms BM; van Berckel BNM; Le Bastard N; van der Flier WM; Scheltens P; Teunissen CE
Alzheimers Dement (Amst); 2021; 13(1):e12182. PubMed ID: 33969174
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest.
Dakterzada F; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Piñol-Ripoll G
Front Aging Neurosci; 2021; 13():604119. PubMed ID: 33746733
[TBL] [Abstract][Full Text] [Related]
9. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.
Kaplow J; Vandijck M; Gray J; Kanekiyo M; Huyck E; Traynham CJ; Esquivel R; Fagan AM; Luthman J
Alzheimers Dement; 2020 Jan; 16(1):144-152. PubMed ID: 31914216
[TBL] [Abstract][Full Text] [Related]
10. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology.
Silva-Spínola A; Leitão MJ; Nadal A; Le Bastard N; Santana I; Baldeiras I
Alzheimers Res Ther; 2024 Mar; 16(1):51. PubMed ID: 38454502
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE
Nojima H; Ito S; Kushida A; Abe A; Motsuchi W; Verbel D; Vandijck M; Jannes G; Vandenbroucke I; Aoyagi K
Ann Clin Transl Neurol; 2022 Dec; 9(12):1898-1909. PubMed ID: 36321325
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer's pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform.
Martínez-Dubarbie F; Guerra-Ruiz A; López-García S; Lage C; Fernández-Matarrubia M; Infante J; Pozueta-Cantudo A; García-Martínez M; Corrales-Pardo A; Bravo M; López-Hoyos M; Irure-Ventura J; Sánchez-Juan P; García-Unzueta MT; Rodríguez-Rodríguez E
Alzheimers Res Ther; 2023 Oct; 15(1):163. PubMed ID: 37784138
[TBL] [Abstract][Full Text] [Related]
13. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
14. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
[TBL] [Abstract][Full Text] [Related]
15. Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.
Leuzy A; Mattsson-Carlgren N; Cullen NC; Stomrud E; Palmqvist S; La Joie R; Iaccarino L; Zetterberg H; Rabinovici G; Blennow K; Janelidze S; Hansson O
Alzheimers Dement; 2023 Jul; 19(7):2994-3004. PubMed ID: 36681387
[TBL] [Abstract][Full Text] [Related]
16. Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology.
Figdore DJ; Wiste HJ; Bornhorst JA; Bateman RJ; Li Y; Graff-Radford J; Knopman DS; Vemuri P; Lowe VJ; Jr CRJ; Petersen RC; Algeciras-Schimnich A
Alzheimers Dement (Amst); 2024; 16(1):e12545. PubMed ID: 38304322
[TBL] [Abstract][Full Text] [Related]
17. Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer's disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study.
Motta C; Di Donna MG; Bonomi CG; Assogna M; Chiaravalloti A; Mercuri NB; Koch G; Martorana A
Alzheimers Res Ther; 2023 Aug; 15(1):144. PubMed ID: 37649105
[TBL] [Abstract][Full Text] [Related]
18. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort.
Amft M; Ortner M; Eichenlaub U; Goldhardt O; Diehl-Schmid J; Hedderich DM; Yakushev I; Grimmer T
Alzheimers Res Ther; 2022 Apr; 14(1):60. PubMed ID: 35473631
[TBL] [Abstract][Full Text] [Related]
19. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ
Bayart JL; Hanseeuw B; Ivanoiu A; van Pesch V
J Neurol; 2019 Sep; 266(9):2304-2311. PubMed ID: 31179518
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
